bemnifosbuvir + rosuvastatin

**Bemnifosbuvir (AT-527)** is an investigational oral antiviral drug that acts as a prodrug of a guanosine nucleotide analog. It is metabolized in the body to its active form, which potently inhibits viral RNA-dependent RNA polymerase (RdRp), thereby blocking replication of viruses such as SARS-CoV-2 and hepatitis C virus (HCV). Bemnifosbuvir has demonstrated strong in vitro and clinical activity against both HCV and SARS-CoV-2, with favorable safety and pharmacokinetic profiles. The drug was originally developed by Atea Pharmaceuticals and licensed to Roche for further development[1][2][3][4][5][6][8]. **Rosuvastatin** is a widely approved statin medication used to lower cholesterol levels by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This entry refers to the combination of bemnifosbuvir (AT-527) with rosuvastatin; however, there is no evidence that this specific combination exists as a marketed or investigational fixed-dose product. Each component retains its individual mechanism of action.

Brand names

Crestor

Other names

bemnifosbuvirAT-511AT511AT 511